With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

Illumina (ILMN) has been grinding higher over the past month, even though the stock is still down over the past year, raising a simple question for investors: is this quiet rebound worth leaning into?

Illumina (ILMN) shares have shown steady movement recently, catching the attention of investors looking at biotech trends. With its latest quarterly performance, investors are considering how ongoing ...

Illumina's stock has seen a modest increase in its Fair Value Estimate, rising from $113.58 to $117.74. This reflects improved analyst confidence in the company's future prospects. This change comes ...

Ampli1™ LowPass Kit applications include the characterization and investigation of genomic heterogeneity and evolution in tumor cell populations such as individual circulating tumor cells (CTCs).

Illumina is an applied genomics technology company that was founded in 1998 with the mission statement: ‘To improve human health by unlocking the power of the genome’. Over the past two decades, ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the ...